Published in
Taylor and Francis Group, Expert Opinion on Drug Safety, 1(19), p. 69-82, 2019
DOI: 10.1080/14740338.2020.1703946
Links
Tools
The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 